Needham analyst Michael Matson maintained a Buy rating on Atricure (ATRC – Research Report) today and set a price target of $55.00. The company's shares closed last Monday at $40.71, close to its 52-week low of $32.84. According to TipRanks.com, Matson is a 3-star analyst with an average return of 2.3% and a 46.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $70.33, implying a 70.4% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-thinks-atricures-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral